EUCTR2010-021394-37-SK进行中（未招募）1 期
MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976
CB Pharma SA0 个研究点目标入组 345 人开始时间: 2010年12月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 345
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written informed consent form is signed and dated by the subject or legal representative.
- •2. Subject/legal representative is considered reliable and capable of adhering to the protocol, visit schedule, and medication application according to the judgment of the investigator.
- •3. Subject is male or female, =18 years of age.
- •4. Subject has idiopathic Parkinson’s disease with at least 2 of the following cardinal signs being present: bradykinesia, resting tremor, rigidity or postural instability, and without any other known or suspected cause of Parkinsonism.
- •5. Subject has a Hoehn and Yahr stage score =4.
- •6. Subject has a total NMSS score =40.
- •7. If the subject is receiving anticholinergics, monoamine oxidase (MAO) B inhibitors, or amantadine, he/she must have been on a stable dose for at least 28 days prior to the Baseline Visit and must be maintained on that dose for the duration of the study.
- •8. If the subject is taking levodopa (L-DOPA), he/she must be on a stable dose of L-DOPA (in combination with benserazide or carbidopa) for at least 28 days prior to the Baseline Visit.
- •9. Female subjects of childbearing potential must agree to use 1 of the following contraceptive methods throughout the course of the study and for 4 weeks after the final removal of study medication:
- •? Oral contraceptives
- •? Intrauterine devices
- •? Double-barrier method
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 75
排除标准
- •1. Subject has previously participated in this study or subject has previously been assigned to treatment in a study of the medication under investigation in this study.
- •2. Subject has participated in another study of an IMP within 30 days prior to the Screening Period or is currently participating in another study of an IMP.
- •3. Subject has a history of chronic alcohol or drug abuse within the previous year.
- •4. Subject has any medical, psychiatric, or cognitive condition that, in the opinion of the investigator, could jeopardize or would compromise the subject’s well being or ability to participate in this study.
- •5. Subject has a known hypersensitivity to any components of the IMP, including sodium metabisulfite.
- •6. Subject has a significant skin disease that would make transdermal drug use inappropriate, including a history of skin sensitivity to adhesives or transdermal medications.
- •7. Subject discontinued from previous therapy with a dopamine agonist after an adequate length of treatment, at an adequate dose, due to lack of efficacy as assessed by the investigator.
- •8. Subject is receiving therapy with 1 of the following drugs, either concurrently or within 28 days prior to the Baseline Visit: alpha-methyl dopa, metoclopramide, reserpine, neuroleptics (except specific atypical neuroleptics: olanzapine, ziprasidone, aripiprazole, clozapine, and quetiapine), MAO-A inhibitors, methylphenidate, amphetamine, or other dopamine agonists (DAs).
- •9. Subject is receiving central nervous system (CNS) therapy (eg, sedatives, hypnotics, selective serotonin reuptake inhibitors [SSRIs], anxiolytics, or other sleep-modifying medication) unless dose has been stable daily for at least 28 days prior to the Baseline Visit and is likely to remain stable for the duration of the study.
- •10. Subject has evidence of an ICD according to the mMIDI at the Screening Visit (Visit 1), confirmed by a positive structured clinical interview.
- •11. Subject is pregnant or lactating.
- •12. Subject is treatment naive, not taking any Parkinson’s disease medication.
- •13. Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response (Yes”) to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening.
研究者
相似试验
进行中（未招募）
1 期
Placebo-controlled study in patients with Parkinson's disease to evaluate the effect of rotigotine on nonmotor symptomsParkinson's diseaseMedDRA version: 14.1Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-021394-37-BECB Pharma SA345
进行中（未招募）
不适用
Placebo-controlled study in patients with Parkinson's disease to evaluate the effect of rotigotine on nonmotor symptomsMedDRA version: 14.1Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersParkinson's diseaseEUCTR2010-021394-37-DECB Pharma SA345
进行中（未招募）
不适用
Multicenter, double-blind, placebo controlled, parallel-group, phase IV study to assess the effect of rotigotine on non-motor symptoms in patients with idiopathic parkinson’s diseaseParkinson's diseaseEUCTR2010-021394-37-HUCB Pharma SA345
进行中（未招募）
不适用
Placebo-controlled study in patients with Parkinson’s disease to evaluate the effect of rotigotine on nonmotor symptomsParkinson's diseaseEUCTR2010-021394-37-ATCB Pharma SA345
进行中（未招募）
不适用
Placebo-controlled study in patients with Parkinson’s disease to evaluate the effect of rotigotine on nonmotor symptomsMedDRA version: 14.1Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersParkinson's diseaseEUCTR2010-021394-37-BGCB Pharma SA345